Eton Pharmaceuticals Announces Acquisition of FDA-Approved Rare Disease Product, Betaine Anhydrous for Oral Solution
13 September 2022 - 11:00PM
Eton Pharmaceuticals (“Eton” or “the Company”) (Nasdaq: ETON), an
innovative pharmaceutical company focused on developing and
commercializing treatments for rare diseases, today announced the
acquisition of betaine anhydrous for oral solution.
"We are excited to add another FDA-approved rare disease product
to our growing metabolic genetics portfolio. Betaine shares the
same prescriber base as our carglumic acid tablets, so it is an
attractive opportunity to leverage our existing commercial
infrastructure. We plan to integrate the product later this year
and expect the transaction to be accretive to 2023 earnings,” said
Sean Brynjelsen, CEO of Eton Pharmaceuticals. “This acquisition
allows us to further advance our mission of commercializing
products for small, underserved orphan populations, and we will
continue to seek out attractive late-stage rare disease products to
expand our portfolio.”
Betaine anhydrous for oral solution targets a population of
fewer than 2,000 patients in the United States, with an estimated
market of $10 million annually.
About Eton PharmaceuticalsEton Pharmaceuticals,
Inc. is an innovative pharmaceutical company focused on developing,
acquiring, and commercializing treatments for rare diseases. The
Company currently commercializes ALKINDI SPRINKLE® and Carglumic
Acid tablets and has four additional rare disease products under
development, including dehydrated alcohol injection and the ZENEO®
hydrocortisone autoinjector. For more information, please visit our
website at www.etonpharma.com.
Investor Relations:Lisa M. Wilson, In-Site
Communications, Inc.T: 212-452-2793E: lwilson@insitecony.com
Source: Eton Pharmaceuticals
Eton Pharmaceuticals (NASDAQ:ETON)
Historical Stock Chart
From Mar 2024 to Apr 2024
Eton Pharmaceuticals (NASDAQ:ETON)
Historical Stock Chart
From Apr 2023 to Apr 2024